Patents by Inventor Haiwen WAN

Haiwen WAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidinyl group-containing tricyclic compound serving as c-Met inhibitor
    Patent number: 12122780
    Abstract: Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: October 22, 2024
    Assignee: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD.
    Inventors: Xile Liu, Charles Z. Ding, Shuhui Chen, Lihong Hu, Haiwen Wan
  • Compounds containing benzosultam
    Patent number: 11718610
    Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: August 8, 2023
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Xile Liu, Charles Z. Ding, Shuhui Chen, Lihong Hu, Haiwen Wan, Xiu Jiang
  • COMPOUNDS CONTAINING BENZOSULTAM
    Publication number: 20230183230
    Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.
    Type: Application
    Filed: April 26, 2021
    Publication date: June 15, 2023
    Inventors: Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Haiwen WAN, Xiu JIANG
  • PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR
    Publication number: 20230056559
    Abstract: Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.
    Type: Application
    Filed: January 22, 2020
    Publication date: February 23, 2023
    Inventors: Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Haiwen WAN
  • Quinazoline compound for EGFR inhibition
    Patent number: 11040984
    Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: June 22, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Xile Liu, Charles Z. Ding, Shuhui Chen, Lingyun Wu, Lihong Hu, Haiwen Wan
  • QUINAZOLINE COMPOUND FOR EGFR INHIBITION
    Publication number: 20200190107
    Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
    Type: Application
    Filed: December 29, 2017
    Publication date: June 18, 2020
    Inventors: Xile LIU, Charles Z. DING, Shuhui CHEN, Lingyun WU, Lihong HU, Haiwen WAN
  • Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
    Patent number: 10053477
    Abstract: Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 21, 2018
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Zhaozhong Ding, Minghui Zhang, Shuhui Chen, Xile Liu, Yidong Zhu, Chuanwen Fan, Baoping Zhao, Long Zhang, Yingying Yang, Qingmei Zheng, Shansong Zheng, Haiwen Wan, Jinqing Hu
  • SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE
    Publication number: 20170129909
    Abstract: Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 29, 2015
    Publication date: May 11, 2017
    Applicant: QUILU PHARMACEUTICAL CO., LTD.
    Inventors: Zhaozhong DING, Minghui ZHANG, Shuhui CHEN, Xile LIU, Yidong ZHU, Chuanwen FAN, Baoping ZHAO, Long ZHANG, Yingying YANG, Qingmei ZHENG, Shansong ZHENG, Haiwen WAN, Jinqing HU